---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-140010"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:48:57.161075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3

## Summary
- Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.
- Fully prepaid $11.0M SVB loan in May 2023; now debt-free; restricted cash of $13.9M released.
- Interim clinical data from TCR-T Library Phase 1/2 trial expected Q3 2023; cryopreserved products manufactured.
- Amended Precigen license: eliminated all royalties and milestones; retained exclusive rights to TCRs using Sleeping Beauty.
- Cash $37.4M at March 31; expects cash into Q4 2023; 2023 operating outflows $35-40M.

## SEC filing metadata
- accession: 0001193125-23-140010
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/0001193125-23-140010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/d459099d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-140010
- JSON: https://secwatch.observer/filing/0001193125-23-140010.json
- Plain text: https://secwatch.observer/filing/0001193125-23-140010.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.0 million, EPS $(0.04) per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: $10.0 million
  - EPS: $(0.04) per share
  - Result: reported results
  source text: Net loss was $10.0 million, or $(0.04) per share, for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523140010/0001193125-23-140010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.